About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Augurex Announces Expansion of Availability of the JOINTstat® Diagnostic Test for Rheumatoid Arthritis with MitogenDx

By: via Business Wire
  • Augurex has partnered with MitogenDx to expand access to JOINTstat® testing across Canada, improving physician and patient access to advanced tools for rheumatoid arthritis (RA) diagnosis and monitoring.
  • JOINTstat® is a Health Canada-approved Class II in vitro diagnostic test that detects 14-3-3eta, a joint-derived biomarker that complements existing markers to improve diagnostic sensitivity and supports ongoing disease monitoring.
  • This partnership enhances access to a leading diagnostic test for RA, supports treatment optimization, and improves outcomes for Canadians living with the disease.

Augurex Life Sciences Corp., a leader in autoimmune-based diagnostics, today announced an agreement with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology diagnostic testing. Under this agreement, MitogenDx will offer the JOINTstat® blood test, expanding access to advanced rheumatoid arthritis (RA) diagnostic testing and disease monitoring for clinicians and patients across Canada.

“Our partnership with MitogenDx represents a major step toward expanding access to JOINTstat® in Alberta and across Canada,” said Neil Klompas, Chief Executive Officer of Augurex. “MitogenDx’s leadership and reputation in autoimmunity make them an ideal partner to help clinicians not only diagnose rheumatoid arthritis earlier, but also monitor disease progression more effectively, improving outcomes for patients across the country.”

JOINTstat® is a Health Canada Class II in vitro diagnostic blood test that detects 14-3-3eta, a biomarker approved for diagnosing and monitoring RA. Elevated levels are associated with more severe disease and an increased risk of joint damage, and 14-3-3eta complements existing markers to improve diagnostic sensitivity, particularly in early and seronegative RA. 14-3-3eta also provides valuable insight into disease progression and treatment response, helping clinicians make more informed therapeutic decisions and optimize long-term patient outcomes.

MitogenDx, based in Calgary, Alberta, is a leading specialty laboratory recognized for its expertise in autoimmune and connective tissue disease testing. Founded by Dr. Marvin Fritzler, a pioneer in rheumatology research and diagnostics, MitogenDx provides high-quality, clinically relevant testing that supports informed patient management.

The integration of JOINTstat® into MitogenDx’s testing portfolio marks an important advancement in precision diagnostics and autoimmune disease care in Canada. The test will be available to ordering physicians through MitogenDx’s laboratory network on January 1, 2026, reinforcing Augurex’s continued growth and momentum in expanding access to advanced autoimmune diagnostics globally.

“We are proud to work with Augurex, one of Canada’s leading diagnostics developers in the field of autoimmunity, to bring JOINTstat® to clinicians and patients across Canada,” said Dr. Marvin Fritzler, MD, PhD, Founder and Medical Director of MitogenDx. “Rheumatologists increasingly need biomarkers that help guide treatment decisions beyond diagnosis. JOINTstat® provides that next level of insight by helping track disease progression and therapeutic response, which can directly improve patient outcomes.”

About Augurex

Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. JOINTstat® (14-3-3eta for Rheumatoid Arthritis) is approved in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. 14-3-3eta testing is available in the U.S. through leading U.S. clinical laboratories through diagnostic tests developed by such laboratories. SPINEstat® (Anti-14-3-3eta Multiplex for Axial Spondyloarthritis) is approved in Canada and Great Britain, and expands Augurex’s diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.

About MitogenDx

MitogenDx Corporation is a Canadian specialty medical laboratory focused on autoimmune and rheumatology diagnostics. Founded by Dr. Marvin Fritzler, MitogenDx provides advanced testing for clinicians nationwide, integrating scientific innovation with clinical expertise to improve diagnostic precision and patient outcomes. Learn more at www.mitogendx.com.

“MitogenDx’s leadership and reputation in autoimmunity make them an ideal partner to help clinicians not only diagnose rheumatoid arthritis earlier, but also monitor disease progression more effectively, improving outcomes for patients across the country."

Contacts

Nima Mazinani, 778-558-2439

More News

View More
Advanced Micro Devices Eyes $300 as AI Demand Surges
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD AMZN GOOGL MSFT NVDA ORCL
Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects
Via MarketBeat
Tickers AMD NVDA QCOM
3 Rare Earth Stocks Powering America’s Critical Minerals Boom
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CRML LAC MP
Why Analysts Are Upgrading Ratings After Klarna's IPO
Via MarketBeat
Topics Initial Public Offering
Tickers AFRM BAC GAP JPM KLAR WMT
Palantir’s New Healthcare Deal Boosts AI and Data Reach
Via MarketBeat
Topics Artificial Intelligence
Tickers ONMD PLTR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.